Research programme: Janus kinase inhibitors - YM Biosciences Australia

Drug Profile

Research programme: Janus kinase inhibitors - YM Biosciences Australia

Alternative Names: JAK2 inhibitors - Cytopia

Latest Information Update: 01 Apr 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cytopia Research; Myomatrix Therapeutics
  • Developer YM BioSciences Australia
  • Class Small molecules
  • Mechanism of Action Janus kinase-2 inhibitors; Vascular endothelial growth factor receptor-1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Cardiovascular disorders; Pulmonary arterial hypertension

Most Recent Events

  • 01 Apr 2014 Discontinued for Cancer in Australia (unspecified route)
  • 01 Apr 2014 Discontinued for Cardiovascular disorders in USA (unspecified route)
  • 01 Apr 2014 Discontinued for Pulmonary arterial hypertension in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top